William Blair analyst Matt Larew has maintained their bullish stance on TECH stock, giving a Buy rating on October 24.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matt Larew has given his Buy rating due to a combination of factors that highlight both challenges and opportunities for Bio-Techne. Despite a top-line miss driven by weaker-than-expected performance in the Protein Sciences segment, the company’s profitability exceeded expectations. This indicates a strong underlying financial health, which is a positive sign for potential investors.
Additionally, there are encouraging signs of stabilization in U.S. academia and continued strength in large pharmaceutical partnerships, which could drive future growth. While there are concerns regarding order timing and a more challenging comparison in the upcoming quarter, the stock’s valuation remains attractive. Bio-Techne’s shares trade at a premium compared to peers but are still below their 15-year average, suggesting potential for upside. These factors collectively support Larew’s Buy rating on the stock.
In another report released on October 24, TR | OpenAI – 4o also upgraded the stock to a Buy with a $73.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year.